Genmab A (GMAB) Depreciation & Amortization (CF) (2024 - 2026)

Genmab A has reported Depreciation & Amortization (CF) for 3 years, with the latest figure at $16.0 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 33.33% year-over-year to $16.0 million; the trailing twelve-month figure through Mar 2026 stood at $80.0 million (up 12.68% YoY), and the FY2025 full-year result was $16.0 million, up 45.45% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $16.0 million, down from $39.0 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $39.0 million in Q3 2025, with the low at $11.0 million in Q1 2024.
• Historically, Depreciation & Amortization (CF) has averaged $23.1 million across 3 years, with a median of $23.0 million in 2024.
• Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) grew 8.33% — and 2026, when it jumped 33.33%.
• Genmab A's Depreciation & Amortization (CF) stood at $36.0 million in 2024, then climbed by 8.33% to $39.0 million in 2025, then slumped by 58.97% to $16.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $16.0 million (Q1 2026), $39.0 million (Q3 2025), and $25.0 million (Q2 2025), per Business Quant data.